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ABSTRACT 
 
Much remains to be understood regarding the molecular mechanisms controlling stem cell fate.  
Through studies in human pluripotent stem cells (hPSCs), I have identified SGK196, an atypical 
kinase of relatively unknown function, as a novel regulator of cell fate and the TGFβ family 
signaling pathway.  SGK196 depletion in human embryonic stem cells (hESCs) inhibits neural 
induction and enhances mesoderm induction, while SGK196 overexpression represses mesoderm 
and endoderm induction.  SGK196 negatively regulates TGFβ family signaling by interacting 
with and promoting the degradation of TGFβ family receptors.  Interactions were observed to 
occur within the SGK196 transmembrane (TM) domain.  Mutation of specific Asn, Asp, and His 
residues in the SGK196 TM domain resulted in the diminished degradation of TGFβ family 
receptors and reduced interactions with the type I BMP receptor (BMPR1B), suggesting that 
these polar residues may play a key role in arbitrating SGK196 activity.  The functional effects 
of Sgk196 in Xenopus laevis animal caps and embryos are in agreement with the results in 
hESCs.  Defects in Sgk196 depleted Xenopus embryos include impaired development of neural 
tissues and increased development of mesodermal tissues.  Overall, I demonstrate that SGK196 
is an essential regulator of stem cell fate determination and early development. Through 
uncovering the regulatory mechanism of SGK196 I unveil valuable insight into receptor-level 
regulation of the TGFβ family pathway.  
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CHAPTER 1 
 
INTRODUCTION 
 
 
Human embryonic stem cells (hESCs) are pluripotent stem cells (PSCs) derived from the inner 
cell mass of blastocyst-stage human embryos, possessing the remarkable ability to self-renew 
almost indefinitely in culture and give rise to derivatives of all three embryonic germ layers.  In 
the interest of advancing methods to generate homogenous cell types from human PSCs (hPSCs) 
for therapeutic applications and the study of normal and abnormal human developmental 
processes, the mechanisms that control pluripotency, direct differentiation and early 
embryogenesis are areas of active investigation (Rajamohan et al., 2013).  Mouse ESCs (mESCs) 
also serve as an in vitro model for mammalian embryos and share some conserved properties 
with hESCs, including expression of pluripotency transcription factors SOX2, OCT4, and 
NANOG.  However mouse and human ESCs exhibit differences in morphology and cell cycle, 
and utilize distinct signaling networks involved in maintaining pluripotency (Ginis et al., 2004, 
Yeo and Ng, 2013).  mESCs require leukemia inhibitory factor acting through the Janus Kinase-
signal transducer and activator (JAK/STAT) pathway and Bone morphogenic protein 4 (BMP4) 
to maintain pluripotency.  Activation of the JAK/STAT pathway was shown to be insufficient to 
prevent differentiation in hESCs (Humphrey et al., 2004, Daheron et al., 2004).  BMP4 is an 
inducer of mesoderm and trophoblast lineages in hESCs (Zhang et al., 2008, Xu et al., 2002).  In 
hESCs, signaling is induced by the basic fibroblast growth factor (FGF) and Activin/Nodal 
ligands to support pluripotency (Yeo and Ng, 2013).  Considering these observed species 
specific differences, hESCs remain the ideal in vitro tool to investigate the molecular and cellular 
processes of human development.   
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 Thus far, studies in hPSCs have indicated the signaling intensity and crosstalk of the fibroblast 
growth factor, insulin growth factor (IGF), Wnt, and Transforming Growth Factor (TGF) β 
family pathways play important roles in the cellular decisions between self-renewal and distinct 
differentiation states (Dalton, 2013). The intricacy of the signals that mediate fate decisions of 
hPSCs are reflected by the concerted actions of a large number of extracellular factors and 
complex cytoplasmic and nuclear networks from multiple pathways (Vazin and Freed, 2010, 
Hodonsky et al., 2013, Boyer et al., 2005). Many questions remain on the mechanistic details 
surrounding these signaling events, as well as their effects in vivo.   
 
Of the pathways investigated in hESCs, the role of the TGFβ family signaling pathway in hESC 
pluripotency and lineage specification has been extensively documented. Present throughout all 
metazoans, the TGFβ family pathway controls diverse biological processes including 
differentiation, apoptosis, migration, and proliferation at both the cellular and developmental 
levels (Moustakas and Heldin, 2009).  Unsurprisingly, the aberrant signaling of the TGFβ family 
pathway is linked to numerous disease states (Gordon and Blobe, 2008, Waite and Eng, 2003).  
The TGFβ family pathway is comprised of two branches: TGFβ/Activin/Nodal and the bone 
morphogenic protein (BMP) signaling.  Signaling of the TGFβ family pathway is mediated 
through more than 30 ligands, including TGF-βs, BMPs, activins, nodal, and seven type I and 
five type II serine/threonine kinase receptors (Moustakas and Heldin, 2009).  The binding of 
ligands to a specific type II receptor dimer leads to the recruitment of a type I receptor dimer and 
subsequent formation of a hetero-tetrameric complex.  Within this complex, the constitutively 
active type II receptor phosphorylates the type I receptor, leading to the activation of its kinase 
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activity and the subsequent phosphorylation of receptor-regulated (R) Smads (R-Smads; 1,5,8 for 
BMP and 2,3 for TGFβ/Activin/Nodal signaling).  Phosphorylated R-Smads then complex with a 
common-mediator (Co) Smad, Smad4, allowing for nuclear translocation and interaction with 
other co-factors to mediate transcriptional regulation of target genes (Shi and Massagué, 2003, 
Moustakas and Heldin, 2009).  Signaling may be further attenuated by inhibitory (I) Smads 6 and 
7 (Moustakas and Heldin, 2009).   
 
The frog Xenopus has contributed greatly to our understanding of the role of various signaling 
pathways in controlling embryonic development. For instance, it was work done in the Xenopus 
system that first demonstrated an instrumental role for TGF-β signaling in the formation of the 
mesoderm (Smith, 1987, Slack et al., 1987, Kimelman and C. Bjornson, 2004, Harland and 
Grainger, 2011). This early work was soon followed by the discovery of key antagonistic 
ligands: noggin, chordin and cerberus (Bouwmeester et al., 1996, Zimmerman et al., 1996, 
Piccolo et al., 1996, Piccolo et al., 1999), which led to our fundamental understanding that the 
BMP pathway inhibition is required for induction of the nervous system.  
 
Both the TGFβ/Activin/Nodal and BMP signaling branches have also been shown to profoundly 
impact the fate decisions of hESCs. The TGFβ/Activin/Nodal pathway supports pluripotency, as 
demonstrated by the positive regulation of the pluripotency-maintenance transcription factor  
NANOG, exhibited by the inhibitory effects of NANOG on BMP mediated differentiation 
(Suzuki et al., 2006).  In contrast, the BMP pathway alters the regulatory activities of OCT4 and 
thus suppresses pluripotency (Wang et al., 2012).  In addition to regulating pluripotency, 
TGFβ/Activin/Nodal signaling can mediate endoderm differentiation (D'Amour et al., 2005, Teo 
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et al., 2012), while BMP signaling has been shown to induce mesoderm, trophoblast, and 
extraembryonic lineages (Xu et al., 2002, Zhang et al., 2008).  Conversely, inhibition of the BMP 
pathway alone or in combination with the TGFβ/Activin/Nodal pathway, leads to the induction 
of neural differentiation of hPSCs (Zhou et al., 2010, Chambers et al., 2009, Kim et al., 2010).     
 
The capacity of the TGFβ family pathway to elicit a plethora of biological outcomes requires 
tightly controlled spatial and temporal regulation of the signaling components at multiple levels. 
Extracellular regulation by ligand antagonists, cytosolic regulation by inhibitory Smads (I-
Smads) and modulation of R-Smad activity, and nuclear transcriptional regulation by Smad 
interaction with co-activators/co-repressors have been reported (Miyazono, 2000, Massagué et 
al., 2005, Bruce and Sapkota, 2012, Miyazono et al., 2006).  Regulation at the receptor level is 
particularly important due to the impact changes in receptor levels and activities have on 
downstream signaling.  Such regulation has been demonstrated by the functional interactions of 
the receptors with other regulators, including co-receptor betaglycan (Bilandzic and Stenvers, 
2011, Blobe et al., 2001, Lewis et al., 2000), pseudoreceptor BAMBI (Onichtchouk et al., 1999), 
FKBP12 (Chen et al., 1997, Okadome et al., 1996, Huse et al., 1999), DRAGON (Samad et al., 
2005), RGMa (Babitt et al., 2005), and more recently Jiriaya (Aramaki et al., 2010).  Given the 
broad implications of the TGFβ family pathway in the regulation of pluripotency and early 
lineage specification of hPSCs, a better delineation of the repertoire of TGFβ family regulators 
and associated mechanisms, especially at the receptor level, is essential for a deeper 
understanding of the molecular programs that govern fate determination of hPSCs.   
To identify novel signaling regulators of cell fate specification, I performed a shRNA screen 
directed against human kinases in NTERA-2 cells, a human embryonal carcinoma cell line 
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derived from the stem cells of a teratocarcinoma risen from transformed germ cells.  These cells 
are often referred to as the malignant counterpart of hESCs, as they possess limited capacity to 
differentiate into other cell types and share similarities with hESCs, including morphology of 
which growth as tight compact colonies with defined borders and the expression of pluripotency 
transcription factors OCT4, SOX2, and NANOG, are associated with the state of pluripotency 
(Pal and Ravindran, 2006, Przyborski et al., 2004).  Upon loss of pluripotency and 
differentiation, colonies flatten and spread out and there is a reduction in pluripotency 
transcription factors.  Relative to hESCs, NTERA-2 cell culture requires less time and resources, 
and thus serves as an ideal platform for initial high volume screening.  Primarily based upon my 
observations on morphological changes, in my screen I identified SGK196, and went on to 
discover this molecule to be a key regulator of hESC multi-lineage specification.   
 
SGK196 is single-pass transmembrane receptor containing a serine/threonine kinase domain.  
Suggestive of its functional significance, SGK196 has homologs present throughout the genomes 
of a variety of species, including mouse, zebrafish, Xenopus, and green anole (NP_083313.1, 
NP_001007415.1, NM_001095489.1, XP_003222408.1).  SGK196 belongs to an interesting 
class of kinases, termed pseudokinases, predicted to be inactive based on the lack of one or more 
of the three key residues each within conserved motifs known to be essential for kinase activity 
(Boudeau et al., 2006).  The kinase domain of SGK196 deviates from all three conserved 
residues (Boudeau et al., 2006).  Pseudokinases are distributed throughout the different kinase 
subfamilies, representing roughly 10% of the kinome.  Despite being predicted to be inactive, 
some pseudokinases have been found to possess kinase activity, while others have been shown to 
regulate active kinases, or act as signaling scaffolds (Zeqiraj and van Aalten, 2010).  Much 
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remains to be characterized of this understudied class of proteins.  Interestingly, it has been 
reported SGK196 exhibited substrate specific kinase activity on O-mannose but the mechanism 
by which this occurs is not clear (Boudeau et al., 2006, Yoshida-Moriguchi et al., 2013).  
SGK196 knockout mice were reported to develop hydrocephalus (Vogel et al., 2012), however 
mechanistic studies clearly linked to the biological role of SGK196 remains to be addressed.   
 
SGK196 depletion was found to enhance mesoderm differentiation but inhibit neural 
differentiation of hESCs.  Conversely, overexpression of SGK196 resulted in the inhibition of 
both mesoderm and endoderm differentiation.  I demonstrated that SGK196 is a negative 
regulator of TGFβ family signaling and showed that the degradation of, the TGFβ family 
receptors and interaction with the type I BMP receptor (BMPR1B), was reduced upon the 
mutation of the Asn, Asp, and His amino acid residues within the SGK196 transmembrane 
domain.  Thereby, these results suggest interactions occurring within the SGK196 
transmembrane domain are linked to the ability of SGK196 to promote TGFβ family receptor 
degradation.  I extended the functional study of SGK196 to the in vivo Xenopus model and 
showed that SGK196 depletion resulted in developmental abnormalities in neural and mesoderm 
tissues and axis formation. Together, I reveal SGK196 as a key regulator of stem cell fate and 
embryonic development, uncover a mechanism underlying SGK196 functional activity, and 
present novel insights into the receptor-level regulation of the TGFβ family signaling pathway.    
 
In this work, I present the first clear demonstration of the functional significance of SGK196 in 
hESC multi-lineage specification and present the first mechanistic characterization accounting 
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for its biological role by revealing SGK196 to be a negative regulator of the TGFβ family 
signaling pathway.   
 
My dissertation research has focused on the characterization of the role of SGK196 in the 
specification of mesoderm, endoderm, and neural lineages through knockdown and 
overexpression studies in hESCs and the effects of Sgk196 depletion on early development in the 
Xenopus model.  The other focus of my work was on the signaling aspect of SGK196 attributed 
to its functional regulation, by dissection of the regulatory mechanism by which SGK196 
negatively regulates the TGFβ family signaling pathway.    
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
 
Antibodies, Growth Factors, and Inhibitors 
Primary Antibodies: SGK196 (ab57908) and α-tubulin (AB11304) were purchased from Abcam 
(Cambridge, MA), P-Smad1/5/8 (9511), P-Smad2 (3108), and Smad2/3 (3102) were purchased 
from Cell Signaling (Beverly, MA), Smad 1/5/8 (SC-6031-R) was purchased from Santa Cruz 
Biotechnology (Dallas, Texas) M2 (anti-FLAG, F1804) was purchased from Sigma-Aldrich, 
anti-HA (MMS-101R-500) was purchased from Covance (Princeton, NJ) BMPR1B (AP2005b) 
was purchased from Abgent (San Diego, CA). Activin A was purchased from R&D Systems 
(Minneapolis, MN), BMP4 and TGF-β1 was purchased from Invitrogen (Grand Island, NY). 
Cycloheximide was purchased from Fisher Scientific (Pittsburg, PA). 
 
Cell Culture 
hESCs H1 and H9 (WiCell, Madison, WI) were maintained in mTeSR medium (STEMCELL 
Technologies, Vancouver, BC, Canada) with daily medium changes, on 6-well plates coated with 
Matrigel (BD Biosciences, Franklin Lakes, NJ). hESCs were passaged at ratios of 1:4 to 1:6 
every 4-6 days using 1mg/mL dispase (Invitrogen, Grand Island, NY). Endoderm (D'Amour et 
al., 2005) and mesoderm (Zhang et al., 2008) differentiation were conducted as previously 
described. Retinoic acid mediated neural differentiation was carried out in DMEM/F12 
supplemented with 1x N2 supplement (Invitrogen) and 10uM retinoic acid (Sigma-Aldrich, St 
Louis, MO). Compound C (EMD Millipore, Billerica, MA) mediated neural differentiation was 
conducted as previously described (Zhou et al., 2010). HEK293T and NTERA2 cells were 
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maintained in DMEM supplemented with 10% FBS, 2mM L-glutamine, 0.1mM non-essential 
amino acids and 1% penicillin/streptomycin.   
 
Plasmid Construction for Overexpression, Knockdown, and Mutant Constructs 
The pSin vector backbone containing the EF1α promoter and IRES-puromycin selection marker 
was used to generate all overexpression constructs, including mKate and mCherry control. Wild-
type and mutant forms of SGK196 and TGFβ family receptor genes were tagged with HA or 
FLAG epitopes and subcloned into the pSin vectors by replacing SOX2 or OCT4 (Addgene, 
16577, 16579, Cambridge, MA). SGK196 deletion mutants were generated by PCR-directed 
mutagenesis. Generation of the SGK196  44-81AA deletion mutant was generated as previously 
described (Science Gateway, 2013a). cDNAs were obtained from Open Biosystems (SGK196, 
8069054; BMPR1B, 6202951; TGFBR1, 30344890; ACVR2B, 40005760, Thermo Scientific, 
Waltham, MA) and Addgene (BMPR2, 23669; UBQLN1, 8663; TGFBR2, 19147; FGFRL1, 
23600).  The pLKO.1-TRC cloning vector (Addgene, 10878) was used in the generation of 
shRNA constructs  
shSGK196-1 (5’GTCTTGGATACACTTAGAttctcgagaaTCTAAGTGTATCCAAGACC 3’)  
and shSGK196-2 (5'AGTTACAGCATTCTACTCTttctcgagaaAGAGTAGAATGCTGTAACT 
3’). Hairpin sequences were designed using http://sirna.wi.mit.edu/. pLKO.1 scramble and 
SGK196-A1 shRNA was purchased from Sigma-Aldrich (NM_032237.x-1338s1c1).  
Overexpression in HEK293T cells was conducted by transient calcium phosphate transfection as 
previously described (Kingston et al., 2001) or stable lentivirus infection (Cohen, 2008). 
Overexpression and knockdown in hESCs were conducted by stable lentivirus infection. 
Lentivirus was generated by co-transfection of pLKO.1 or pSin lentiviral vector of interest with 
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pCMV-dR8.91 and pCMV-VSV-G in HEK293T cells, as described previously (Science 
Gateway, 2013b).  
 
Quantitative Real-Time Polymerase Chain Reaction 
Total RNA was extracted with TRIzol reagent (Invitrogen) according to manufacturer’s 
instructions. cDNA was synthesized using the Improm II Reverse Transcription System 
(Promega, Madison, WI) per manufacturer’s instructions. Quantitative real-time PCR (QPCR) 
was conducted using the SYBR Green JumpStart Taq ReadyMix (Sigma-Aldrich) on a StepOne 
Plus Real Time PCR machine (ABI).  Primer sequences are provided in Table 1. QPCR values 
represent the average of at least three independent trials and error bars represent the standard 
error of the mean. Asterisks indicate a statistical significance of p≤0.05 compared to the control 
within each experimental group, as determined by the Student’s t-test. 
 
Immunoprecipitation and Western Blot Analysis 
Immunoprecipitation of FLAG and HA tagged proteins was carried out using M2 and EZview 
Red Anti-HA Affinity Gel antibody-agarose conjugates (Sigma-Aldrich), respectively, in lysis 
buffer containing 20mM Tris HCl pH 8, 0.1-1% NP-40, 150mM NaCl, 2mM EDTA, 
supplemented with protease inhibitor cocktail (Sigma-Aldrich). After binding and extensive 
washing, bound proteins were eluted by boiling in 2X SDS sample buffer (Biorad, Hercules, 
CA), separated by SDS-PAGE and transferred onto nitrocellulose membranes. Signals were 
detected with ECL reagents (Pierce Thermo Scientific, Rockford, IL). HEK293T cells subjected 
to Western blot analysis were directly lysed in 2X SDS sample buffer. Western blot 
quantifications were done using Image J (Schneider et al., 2012).  
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 Immunostaining 
Cells on coverslips were washed in cold PBS, fixed in 3.7% paraformaldehyde, permeabilized 
with 0.1% Triton X-100 in PBS, and blocked in 5% bovine serum albumin in PBS.  Primary 
antibodies were incubated with samples overnight at 4°C, and detection was carried out using 
Alexa-conjugated secondary antibodies (Invitrogen).  For live staining, cells on coverslips were 
cooled to 4°C, rinsed in cold PBS, and incubated with primary antibody for 30 minutes at 4°C.  
After PBS washes, cells were incubated with Alexa-conjugated secondary antibodies 
(Invitrogen) for one hour at 4°C. Following PBS washes, cells were fixed in 3.7% 
paraformaldehyde for 10 minutes at room temperature.  All coverslip samples were mounted 
with Vectashield Mounting Medium with DAPI (Invitrogen).    
 
Plasma Membrane Staining 
Cells grown on coverslips were incubated with 0.5X concentration of CellMask green plasma 
membrane stain (Invitrogen) in PBS at 37°C for 10-15 minutes. Cells were then fixed with 
prewarmed 3.7% paraformaldehyde at 37°C for 10 minutes then mounted with Vectashield 
Mounting Medium with DAPI (Invitrogen).    
 
Determination of Transmembrane Protein Orientation 
HEK293T cells transfected with N or C terminal HA tagged SGK196 were singularized with 
0.05% Trypsin-EDTA (Mediatech, Manassas, VA) for 40 minutes at 37˚C.  After trypsin 
treatment, cells were neutralized in 10% FBS containing media and pelleted by centrifugation.  
Cells were lysed in 2X SDS sample buffer and subject to Western blot analysis.   
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Luciferase Reporter Assay 
The pID-120-luc reporter construct (kindly provided by Dr. Renhe Xu, University of 
Connecticut, (Lopez-Rovira et al., 2002)) was used to measure BMP signaling and the pARE-
GL3 luciferase reporter (kindly provided by Dr. Yisrael Sidis, Partners Healthcare, (Sidis et al., 
2002)) and FAST1 constructs were used to measure Activin signaling.  Renilla-luciferase 
reporter (Promega, Madison, WI) was used for the internal control.  Reporters were co-
transfected with different quantities of HA-SGK196 in HEK293T cells using Lipofectamine 
2000 (Invitrogen, Grand Island, NY).  24 hours later cells were serum starved overnight then 
treated with ligand for 12 hours.  Samples were prepared according to the manufacturer's 
protocol using the Dual-Luciferase Reporter Assay System (Promega).  Luciferase activity was 
measured with the LUMIstar plate reader (BMG Labtech, Cary, NC).    
 
Animals 
Adult Xenopus laevis were acquired from Nasco (Fort Atkinson, WI). Fertilized eggs were 
obtained according to methods previously published in (Henry and Grainger, 1987), and 
subsequent embryos and larvae were reared according to methods described in (Henry and 
Mittleman, 1995). Developmental staging was based on the descriptions of (Faber and 
Nieuwkoop, 1956). 
 
Sgk196 and In situ Hybridization 
The Xenopus Sgk196 full-length clone was obtained from Open Biosystems (Clone ID: 6868253, 
Thermo Scientific, Waltham, MA) and used to generate digoxygenin (DIG)-labeled RNA sense 
(T3) and antisense (T7) probes. In situ hybridization reactions contained of a range of embryonic 
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stages (st8-41) and were conducted according to the published protocol (Harland, 1991) with a 
few modifications (described in (Malloch et al., 2009).  
 
Morpholino Design and Rescue RNA 
Lissamine-tagged MOs were designed and obtained from Gene Tools (Philmath, OR). The 
SGK196MO targets the translational start site of SGK196, including the downstream region 
adjacent to the start site (5’–TGCAGACACTAGGTTTTCTCTCCAT; translational start site is 
underlined). A commercially available CONMO was used as a standard control and has been 
used in previous studies (Perry et al., 2010, Wolfe and Henry, 2006, Elkins and Henry, 2006). 
To demonstrate the specificity of SGK196MO, an altered SGK196 transcript was generated.  
Primers for the altered SGK196 transcript were designed to include third-base substitutions to 
target the nucleotide binding sequence of SGK196MO in a manner to preserve the original 
protein coding sequence (Forward 5’-BamHI:ATGGAaAGgAAgCCcAGcGTtTGtA and Reverse 
5’-EcoRI: TTACAACATCTCTCGAGTTTCTGCC). Underlined bases refer to the translational 
start site and lowercase bases represent those altered from the original nucleotide sequence. The 
altered Sgk196 cDNA was digested with BamHI and EcoRI, directionally cloned into pCS2+ 
(Clontech, Mountain View, CA) and sequence verified (Carver Biotechnology Center, Urbana, 
IL).  Capped altered sgk196 mRNA noggin mRNA (plasmid provided by Dr. Richard Harland) 
were synthesized from PCR template using the SP6 mMessage mMachine kit (Life 
Technologies).  
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 Microinjection Techniques 
Dejellied two-cell Xenopus embryos were placed in a solution of 5% ficoll in clay dishes 
containing small recesses to hold each individual embryo (Elkins and Henry, 2006, Wolfe and 
Henry, 2006) and injected with MOs, capped mRNAs or combinations of both.  Morpholinos 
were diluted to a concentration of 2 mM in sterile water and each injection was performed either 
one-cell stage embryos or two-cell stage embryos using glass microinjection needles and a 
Narishige micromanipulator (Narishige USA, East Meadow, NY). A pressure injection apparatus 
(Harvard Apparatus, Holliston, MA) was used to deliver specific quantities of morpholino, 
mRNA only and morpholino combined with capped mRNA. Capped mRNA only injections 
required combining the non-toxic dye Fast Green or fluorescent dextran (green) with the mRNA 
sample for visualization. Following injection, embryos were allowed to recover in 1/20X normal 
amphibian media (NAM) through st41 with daily solution changes.  
 
Phenotypes were characterized by changes in morphology. Mild phenotypes were close in size to 
wild-type specimens, but had minor disruptions in axis formation with a clearly developed tail. 
Mild cases also had slightly reduced eye sizes in comparison to wild-type control eyes. Severe 
phenotypes displayed at least two of the following defects. Changes included a dramatically 
reduced body size in comparison with wild-type specimens. There was a significant disruption in 
axis formation that included tails that were greatly reduced or even absent and ectopic tissue 
growth was common. Many of these animals displayed grossly reduced eye sizes (at least 50% 
smaller than the contralateral control eye) or in the most severe cases some animals displayed 
cyclopic phenotypes (statistical analysis described in Elkins and Henry, 2006) 
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 Histology 
Specimens from a range of stages (8-41) were fixed in MEMFA (3.7% formaldehyde, 100mM 
MOPS, 2mM EGTA, 1 mM MgSO4), and stored in methanol at –20°C. For histological 
preparations, specimens were washed in graded ethanol up to 100%, xylene, and embedded in 
Paraplast Plus (Fisher Scientific, Pittsburg, PA). Specimens were sectioned to a thickness of 
8µm, dewaxed in xylene and stained in Harris hematoxylin/Eosin (Fisher Scientific) according to 
published protocols (Humason, 1972).  
 
Animal Cap Assay 
Xenopus embryos at st8 were collected and animal caps were excised according to (Ariizumi et 
al., 2009). Embryos at st8 were placed in 3/4X NAM solution in clay dishes containing 
depressions to hold each individual embryo. The vitelline membrane was removed from each st8 
specimen and animal caps were removed using a finely pulled glass needle, making sure to 
excise only the ectodermal cells of the animal cap and not the adjacent marginal zone which 
might include mesodermal cells. All caps were placed in a clean petri containing 3/4X NAM 
solution overnight in an incubator at 16°C. The next morning, caps were washed in 1/20X NAM 
and monitored for staging in comparison with sibling control embryos until st26-28. Animal caps 
were pooled in groups of 5 caps per tube and processed with sibling control embryos for total 
RNA extraction using Trizol (Invitrogen, Grand Island, NY). 
Total RNA from pooled caps (5 caps/tube) was used for RT-PCR and the presence of the 
following transcripts were examined by PCR: positive control elongation factor 1-alpha (eef1a1; 
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(Krieg et al., 1989)), epidermal marker epidermal cytokeratin (sxk81a1; (Jonas et al., 1989)) and 
pan-neural marker ncam1 (Kintner and Melton, 1987).  For primer sequences see Table 2. 
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CHAPTER 3 
RESULTS 
 
SGK196 is a key regulator of hESC lineage specification 
In search of novel regulators of fate determination of hPSCs, we examined the involvement of a 
subset of human kinases by RNAi.  Kinases were depleted by the use of shRNAs in NTERA2 
cells and the disruption of pluripotency was identified based on cell morphology.  NTERA2 cells 
are a human pluripotent embryonal carcinoma line that exhibits high-level expression of 
pluripotency markers and possesses the capacity for limited multilineage differentiation in vitro 
and in vivo (Pal and Ravindran, 2006, Przyborski et al., 2004).  SGK196 emerged as a potential 
regulator based on the loss of distinct colony borders and cell spreading upon SGK196 depletion 
(Figure 1A).  These screening experiments led to the identification of SGK196 (Figure 1B), an 
atypical transmembrane kinase, as a potential regulator of hPSC fate determination. 
 
I next investigated the role of SGK196 in hESCs. In agreement with the results in NTERA2 
cells, shRNA mediated knockdown of SGK196 in hESCs cultured under feeder-free conditions 
led to noticeable morphological changes including the flattening and spreading of cells (Figure 
1C). These changes are in contrast to control cells, which grew as tight compact cell colonies 
(Figure 1C). Interestingly, SGK196 overexpression did not appear to affect hESC morphology 
(Figure 1D). In my preliminary studies using hESCs cultured under mouse embryonic fibroblast 
feeder conditions, I found that SGK196 depletion resulted in the spontaneous up-regulation of 
endoderm (SOX17, GATA4, GATA6) and mesoderm markers (T, MIXL1) without significantly 
altering the level of neural markers (PAX6, SOX1) or pluripotency markers (OCT4, NANOG, 
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SOX2; data not shown).  SGK196 knockdown and overexpression under feeder-free conditions 
also had minimal effects on the expression of pluripotency markers (Figure 2A and B), 
suggesting that SGK196 may not directly regulate pluripotency.   
 
The observed selective up-regulation of endoderm and mesoderm markers upon SGK196 
depletion indicated an involvement in lineage specification. I therefore induced hESCs to 
differentiate into neural, mesoderm, and endoderm lineages and assessed whether SGK196 
depletion and overexpression affected these differentiation activities. Following treatment with 
Compound C (also known as Dorsomorphin), which has previously been used for neural 
induction of hPSCs (Zhou et al., 2010, Yu et al., 2008), the neural progenitor markers PAX6, 
SOX1 and OTX2 were up-regulated, but were markedly attenuated upon SGK196 depletion 
(Figure 3A). Compound C mediated up-regulation of PAX6, SOX1, and OTX2 was also 
attenuated upon SGK196 overexpression (Figure 3B).  I also treated hESCs with retinoic acid 
(RA), a known inducer of neural differentiation in pluripotent stem cells (Tonge and Andrews, 
2010), and found that PAX6 up-regulation was dramatically impaired upon SGK196 depletion 
(Figure 3C).  SGK196 overexpression exerted minimal effects on RA-induced PAX6 up-
regulation (Figure 3D). 
 
SGK196 depletion and overexpression in hESCs also influenced endoderm and mesoderm 
differentiation. Upon BMP4-mediated mesoderm differentiation, SGK196 depletion further 
elevated the level of mesoderm markers (T and MIXL1; Figure 4A).  Induction of these 
mesoderm markers was inhibited in the presence of overexpressed SGK196 (Figure 4B).  Upon 
Activin A-mediated endoderm induction, SGK196 depletion had minimal effects on the up-
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regulation of endoderm markers (SOX17, GSC, FOXA1; Figure 4C).  Induction of these markers 
was inhibited by SGK196 overexpression (Figure 4D).  SGK196 levels appeared largely 
unaffected during hESC differentiation into the three embryonic lineages.  Thus, SGK196 is 
involved in lineage specification of hESCs during early differentiation.   
 
SGK196 inhibits BMP and TGFβ/Activin signaling  
I next sought to investigate the mechanism by which SGK196 regulates early differentiation in 
hESCs. Previously, Barrios-Rodiles et al. (2005) developed a high-throughput screen to map 
protein-protein interactions within signaling pathways. When applied to the TGFβ family 
signaling pathway, it was found that mouse Sgk196 can interact with type I receptors TGFΒR1 
and BMPR1B, but the function of this interaction was not elucidated.  The observed differential 
regulation of SGK196 on mesoderm/endoderm and neural induction (Figures 3 and 4) is 
reminiscent of the positive and negative roles of TGFβ family signaling on mesoderm/endoderm 
(Zhang et al., 2008, D'Amour et al., 2005) and neural specification (Zhou et al., 2010, Kim et al., 
2010, Chambers et al., 2009), respectfully. Taken together, these observations led us to 
hypothesize that SGK196 may be involved in the regulation of TGFβ family signaling.   
 
SGK196-mcherry fusion proteins expressed in HEK293T cells (Figure 5A), showed 
colocalization with the general plasma membrane stain CellMask (Figure 5B), indicating that 
SGK196 is localized to the plasma membrane. This pattern of membrane localization was 
previously observed for ectopically expressed mouse Sgk196 in COS-7 cells, a monkey kidney 
fibroblast-like cell line (Barrios-Rodiles et al., 2005).  
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Given that SGK196 is localized to the plasma membrane, I assessed the effect of SGK196 
depletion and overexpression on R-Smad phosphorylation. Treatment of hESCs with BMP4 and 
Activin A induced R-Smad1/5/8 and 2/3 phosphorylation, respectively, and upon SGK196 
depletion both ligand-induced R-Smad1/5/8 and 2/3 phosphorylation were elevated (Figures 5C 
and 5D). In contrast, SGK196 overexpression repressed ligand-induced R-Smad1/5/8 and 2/3 
phosphorylation (Figures 5E and 5F). These results suggest that SGK196 acts as a negative 
regulator of BMP and Activin signaling in hESCs.   
 
To ask whether SGK196 played a similar regulatory role in other cell types, I tested the effect of 
SGK196 ectopic expression in HEK293T cells. Consistent with the findings in hESCs, SGK196 
overexpression inhibited BMP4-induced Smad1/5/8 phosphorylation (Figure 6A) and  
Activin /TGFβ-1-induced Smad2/3 phosphorylation (Figure 6B).  In experiments with BMP and 
Activin luciferase reporters carried out in HEK293T cells, ectopic expression of SGK196 
reduced the reporter activity in a dose-dependent manner (Figures 6C and 6D).  Thus, the 
SGK196 regulatory function within the TGFβ family pathway is consistent in HEK293T cells.   
 
Together, I present the first functional characterization of SGK196 as a potential key regulator of 
the TGFβ family signaling pathway. The inhibitory role of SGK196 in the regulation of TGFβ 
family signaling provides a mechanistic explanation for the effects of SGK196 depletion and 
overexpression on endoderm, mesoderm and neuroectoderm differentiation of hESCs. 
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SGK196 promotes the degradation of TGFβ family receptors 
The localization of SGK196 to the plasma membrane (Figure 5A and 5B) and effects of SGK196 
depletion/overexpression on ligand-induced R-Smad phosphorylation (Figure 5C-F; Figure 6A 
and 6B), indicated that SGK196 regulation of TGFβ family signaling may occur at the receptor 
level.  To study the potential SGK196 regulation on the receptor proteins, I ectopically co-
expressed SGK196 with FLAG-tagged TGFBR1 (a type I TGFβ receptor, also referred to as 
ALK5), BMPR1B (a type I BMP receptor, also referred to as ALK6), and BMPR2 (a type II 
BMP receptor) in HEK293T cells.  Upon SGK196 overexpression, the levels of TGFBR1, 
BMPR1B, and BMPR2 (Figures 7A and 3B) were markedly decreased.  SGK196 overexpression 
did not affect the protein levels of UBQLN1, a non-TGFβ family pathway molecule known to 
interact with proteasome and ubiquitin ligases (Lee and Brown, 2012) (Figures 7A and 3B). 
SGK196 overexpression also promoted the degradation of the type II Activin receptor ACVR2B 
protein (Figure 7C).   
 
I next examined the half-life of FLAG-tagged TGFBR1 and BMPR1B in HEK293T cells by 
administering cycloheximide (CHX), an inhibitor of protein synthesis. After a 5-h time course, 
CHX treatment reduced TGFBR1 and BMPR1B levels by 39% and 37%, respectively (Figures 
7D and 7E, respectively). In the presence of HA-SGK196, enhanced degradation of TGFΒR1 
and BMPR1B was observed, with protein levels reduced by 92% and 68%, respectively (Figures 
7D and 7E, respectively). I also assessed whether SGK196 may affect receptor expression by 
examining the mRNA levels of TGFBR1, BMPR1B, TGFBR2 and BMPR2 in hESCs depleted of 
or overexpressing SGK196 (Figure 8A and 8B).  No distinct regulatory patterns were observed. 
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Thus, SGK196 inhibits BMP and TGFβ/Activin signaling by promoting the protein degradation 
of receptors. 
 
The SGK196 transmembrane domain is key for SGK196 function 
The negative regulatory role of SGK196 on the TGFβ/Activin and BMP signaling at the receptor 
level, along with the previously reported potential interaction between mouse Sgk196 with 
TGFΒR1 and BMPR1B (Barrios-Rodiles et al., 2005), led us to test whether SGK196 could 
complex with the TGFβ family receptors and ask if such interactions are essential for the protein 
degradatory function of SGK196.  
 
I performed co-immunoprecipitation (co-IP) experiments to look for possible interactions 
between SGK196 and TGFBR1, BMPR1B, BMPR2, and ACVR2B, all of which were shown to 
be degraded in the presence of ectopic SGK196 (Figure 7A-C).  HEK293T cells were transfected 
with HA-SGK196 and FLAG-tagged TGFβ family receptors and IP was carried out against 
either the HA or FLAG epitope. Tagged proteins were used due to lack of commercially 
available antibodies able to readily detect specific endogenous receptors. To ensure sufficient 
expression of TGFβ family receptors, the TGFβ family receptors were expressed in excess 
relative to the lower levels of SGK196.  Interestingly, the co-IP studies revealed that all the 
TGFβ family receptors examined could complex with SGK196 (Figure 9A-D).  
 
SGK196 is a type II transmembrane receptor 
To investigate the nature of the interaction between SGK196 and the receptors, I first assessed if 
SGK196 was a type I or type II transmembrane protein.  Type I and II proteins are single pass 
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transmembrane proteins that are classified by the N-terminus occurring at either the extracellular 
or cytosolic side, respectfully. SGK196 tagged with the HA epitope at the N (HA-SGK196) or C 
(SGK196-HA) terminus were expressed in HEK293T cells (Figure 10A). Subsequent IF studies 
revealed clear detection of the HA epitope for SGK196-HA under both live as well as fixed 
permeabilized staining conditions (Figure 10C and 10D).  IF detection of the HA epitope for 
HA-SGK196 occurred only under fixed permeabilized conditions (Figure 10C and 10D).  In 
addition, western blot analysis of HEK293T cells expressing SGK196-HA showed trypsin 
treatment dramatically reduced the amount of detectable HA tag of full length SGK196-HA, in 
contrast to the effects observed for HA-SGK196 (Figure 11A and 11B).  A commercial antibody 
raised against the C-terminal region of SGK196 (amino acids 251-350) also detected a reduction 
of HA-SGK196 and SGK196-HA protein levels following trypsin treatment (Figure 11A and 
11B).  These findings indicate SGK196 is a type II transmembrane protein. This is in agreement 
with a study reporting that SGK196 is a protein O-mannose kinase, as illustrated by experiments 
that showed SGK196 was required for the successive phosphorylation of the 6-position on 
specific O-mannosyl trisaccharide substrates (Yoshida-Moriguchi et al., 2013). While it was not 
confirmed, the nature of this reported kinase activity places the SGK196 kinase domain in the 
luminal side of the endoplasmic reticulum/Golgi.    
 
The SGK196 transmembrane domain is important for SGK196-receptor interactions and 
SGK196 activity 
To investigate whether the interaction between SGK196 and the receptors is linked to its protein-
degradatory function, I examined the relationship between SGK196 and BMPR1B to identify the 
region within SGK196 that mediates the interaction. As a type II transmembrane protein, 
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SGK196 is comprised of a cytoplasmic domain (1-20 amino acid; AA), a transmembrane domain 
(TM) (21-43 AA) and an extracellular domain (ECD) (44-350 AA; Figure 1B).  HA-tagged 
SGK196 mutants were generated with the following deletions: 1-81 AA mutant missing the 
majority of the ECD, ∆1-21 AA mutant missing the cytoplasmic region, ∆44-81 AA mutant 
missing a short region between the TM and kinase domain, and the ∆1-43 AA mutant missing 
both the cytoplasmic and TM domains (Figure 12A). All HA-SGK196 mutants containing the 
TM domain retained the ability to co-IP with BMPR1B, independent of the presence of the intact 
ECD or cytoplasmic domain (∆1-21 AA), with the exception of the ∆1-43 AA mutant that 
contains only the ECD (Figure 12B).  This suggests that the ECD, thereby SGK196 kinase 
activity, is dispensable for the SGK196-BMPR1B interaction.  Taking into account the 1-81 AA 
SGK196 fragment, which lacks a majority of the ECD, was sufficient to co-IP with BMPR1B 
and with a BMPR1B mutant lacking the cytoplasmic domain (Figure 12B-D), I inferred the 
SGK196 TM domain (21-43 AA) is likely a major site that mediates the interaction with 
BMPR1B.  While these findings clearly support the SGK196 TM domain to be a necessary 
region for receptor-interactions, it does not rule out the possibility for additional points of 
interactions to exist in the other regions of SGK196.   
 
The HA-SGK196 mutants shown to interact with BMPR1B were all found to be capable of 
promoting BMPR1B and BMPR2 protein degradation (Figure 12E and 12F).  IF against the N-
terminal HA tag of the SGK196 1-81AA, 1-100AA, ∆1-20 AA and the ∆44-81 AA mutants in 
HEK293T cells showed localization patterns similar to the full length SGK196 (Figure 13).  
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To examine the specificity of the interaction between BMPR1B and the SGK196 TM domain, I 
created a chimeric protein by replacing the SGK196 TM domain with the TM domain of 
fibroblast growth factor receptor-like 1 (FGFRL1), a type I topology single-pass transmembrane 
receptor of the FGFR family that lacks an intracellular tyrosine kinase domain (Figure 14A).  
The SGK196 chimera exhibited a reduced capacity to promote the degradation of BMPR1B 
(Figure 14B).  BMPR2 and TGFBR1 was also observed to not be degraded by the SGK196 
chimera (Figure 14C and 14D).  The affinity between the SGK196 chimera and BMPR1B was 
reduced, as shown by the co-IP studies (Figure 14E and 14F).  IF against the N-terminal HA tag 
of the SGK196 chimera displayed distribution patterns similar to wild type SGK196 (Figure 
14G). Although the FGFRL1 TM domain is of a type I orientation in contrast to the type II 
orientation of the SGK196 TM domain, these results indicate that the interactions occurring in 
the SGK196 TM domain and the effects on receptor protein degradation are not nonspecific.   
 
Asn31, Asp39 and His40 in the SGK196 transmembrane domain are critical for mediating 
SGK196 activity and receptor interactions 
Polar residues in the TM domain have been shown to serve as signals to influence endocytic 
trafficking (Reggiori et al., 2000, Popa et al., 2012, Sato et al., 2003). It has been demonstrated 
that the transplantation of three polar residues into the transferrin receptor TM domain can cause 
the down-regulation of recycling transferrin receptors (Zaliauskiene et al., 2000). The SGK196 
TM domain contains Asn, Asp, and His, all of which are polar residues rarely observed in the 
TM domains of single pass proteins (Landolt-Marticorena et al., 1993). With the exception of 
ACVR2A (Activin receptor Type IIA), which contains an Asn, these three polar residues are not 
present in the TM domains of the other TGFβ family receptors. To examine whether these polar 
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amino acids may be involved with SGK196 activity, Asn31, Asp39 and His40 residues in the 
SGK196 TM domain were mutated to Ala (Figure 15A). Interestingly, major loss of SGK196 
degradatory activity for BMPR1B (Figure 15B) was observed upon mutation of all three polar 
residues. The Asn31Ala and the Asp39Ala / His40Ala SGK196 mutants retained the general 
ability to promote BMPR1B degradation (Figure 15B).  The Asp39Ala and His40Ala SGK196 
mutants similarly retained protein degradatory function (data not shown).  These mutants 
exhibited the same effects on TGFBR1, BMPR2, and ACVR2B receptors (Figure 15C-E) 
 
Polar residues in the TM domain have also been shown to influence TM domain interactions 
(Nordholm et al., 2013, Zhou et al., 2001).  The SGK196 Asn31Ala / Asp39Ala / His40Ala 
(triple mutant) exhibited decreased co-IP with BMPR1B (Figure 15F and 15G).  This reduced 
interaction indicates the Asn, Asp, and His polar residues may play a role in mediating the 
interactions with receptors that occur within the SGK196 TM domain.  IF against the N-terminal 
HA tag of the SGK196 Asn31Ala, Asp39Ala / His40Ala , and Asn31Ala / Asp39Ala / His40Ala 
mutants in HEK293T cells showed localization patterns similar to the wild type SGK196  
(Figure 16).  
 
The reduced degradation of and interaction with BMPR1B resulting from the mutation of the 
polar residues in the SGK196 TM domain, further suggests that SGK196 function is contingent 
upon SGK196-receptor interactions occurring at the SGK196 TM domain.  The SGK196 
deletion and chimera mutants were observed to exert similar effects on the degradation of other 
TGFβ family receptors (Figure 12F and 15C-E).  Overall, the findings presented here imply there 
may be a common mechanism of SGK196 to regulate other TGFβ family receptors.   
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SGK196 is essential for Xenopus embryonic development 
The morpholino injections described in this section were performed in collaboration with Kim 
Perry in Dr. Jonathan Henry’s lab.  All insitus were performed by Kim Perry.  The TGFβ family 
pathway plays key roles in a wide array of developmental processes including gastrulation, germ 
layer formation, axis polarization, and the differentiation and patterning of specific organ 
systems (Kitisin et al., 2007, Herpin and Cunningham, 2007). An understanding of the 
developmental and tissue-specific functions of SGK196 requires evaluation in the context of an 
in vivo whole animal system. The frog Xenopus represents a model system for studies of 
vertebrate molecular, cell and developmental biology (Kay BK, 1991, Henry et al., 2008, Sive et 
al., 2000), having played a major role in deciphering the activities of various signaling pathways, 
including the TGFβ/Activin/Nodal and BMP pathways. This is due to the relative ease with 
which one can procure and rear embryonic material, and a powerful array of functional tools that 
have been developed to examine gene function. Here the function of SGK196 was examined 
during embryogenesis in Xenopus.   
 
In situ hybridization were first carried out in embryos over a range of stages (10-36; gastrula 
through early larval stages) to pinpoint the expression of sgk196 during Xenopus early 
development. It was found that sgk196 was expressed throughout all stages of embryonic 
development examined (Figures 17A-5L). Initially, sgk196 mRNA was expressed broadly in 
embryos at st10-12, (Figures 17A-5D), but eventually became more restricted to the developing 
central nervous system including brain, eyes and spinal cord (Figures 17E-L). RT-PCR analyses 
also verified that sgk196 was expressed during all stages examined (Figures 17M). sgk196 
transcripts are present maternally as the original Xenopus sgk196 clone was isolated from eggs.   
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 Next, loss-of-function analyses were carried out to determine the effect of Sgk196 depletion. 
Injecting a morpholino (MO) to block the translation of Xenopus Sgk196 (SGK196MO) led to a 
range of developmental defects. Many defects were associated with the central nervous system, 
including truncated anterior-posterior axes and neural defects (Figures 18A-H). Severe 
phenotypes observed following Sgk196 depletion included embryos with an overall reduction of 
body size, major axis defects, tail malformation, and reduced head and eye sizes  
(Figures 18A and 18B). Some embryos exhibited cyclopia and spina bifida (data not shown). 
Sections of a 40ng SGK196MO injected embryo show disrupted brain development, including 
reduced size and thickness of the neural tube (Figure 18C and 18D). In contrast, there was 
increased development of axial mesodermal tissues including the notochord and somatic 
mesoderm (Figure 18C and 18D). Similar defects were observed to a lesser extent in mild cases 
injected with 20ng SGK196MO (Figure 18E-H). Sgk196 depletion did not alter development of 
the otic vesicles, indicating that the identity of hindbrain tissue, which is involved in otic vesicle 
induction, was still preserved (Gallagher et al., 1996). Impaired development of neuronal tissues 
and increased mesoderm development are reminiscent of the changes detected in differentiating 
hESCs following SGK196 depletion. Injections of SGK196MO also resulted in cloacal defects 
and defective digestive tracts, which appeared to be smaller in diameter and comprised of 
disorganized thickened tissue (Figure 18A and 18E). The severity of defects was dependent on 
the amount of MO injected (Figure 18A-H, 18CC). In contrast, injections of a control 
morpholino (CONMO) had no deleterious effects on development (Figure 18I-L, 18CC).  
To further verify the specificity of the MO injection and in the absence of a reliable antibody for 
Xenopus Sgk196, it was observed that the defects observed following injections of SGK196MO 
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could be rescued by co-injection of a synthetic RNA encoding an altered form of Sgk196, which 
was not targeted by the SGK196MO. While no significant rescue was seen with a lower dose of 
co-injected RNA (454pg), a dose dependent improvement in development was detected using 
higher concentrations of RNA (745pg and 1000pg, respectively Figure 18CC). Sections of an 
embryo co-injected with SGK196MO and 1000pg sgk196 RNA showed relatively normal 
organization of internal tissues (Figure 18Q-T). Injections of the sgk196 RNA at the higher 
1000pg concentration did not result in apparent developmental defects (Figure 18U-X, 18CC). 
 
The increase in mesoderm formation observed following Sgk196 depletion led to the pursuit 
whether this phenotype could be rescued by co-injection of a truncated Activin receptor. A 
previous study (Hemmati-Brivanlou and Melton, 1992) found that the activity of the endogenous 
type II Activin receptor Xar1 could be inhibited by injecting embryos with a dominant negative 
form, ΔXAR1, generated by the truncation of nearly the entire cytoplasmic region which 
includes the serine/threonine kinase domain.  It was found that injection of ΔXAR1 mRNA 
blocked induction of the mesodermal marker brachyury in the marginal zone cells of st11 
Xenopus embryos, and animal cap explants injected with ΔXAR1 expressed higher levels of the 
neural-specific marker ncam. Also, these ΔXAR1 injected Xenopus embryos did not form 
notochord (Hemmati-Brivanlou and Melton, 1992). Our experiments used the same 
concentration of ΔXAR1 mRNA (labeled XAR1DN; 4ng) co-injected with 30ng SGK196MO, 
which resulted in a partial rescue of Xenopus embryos (Figure 18Y-BB; 18CC). There was a 
reduction in the number of severe phenotypes and an increase in mild and normal phenotypes 
following co-injection of XAR1DN mRNA and SGK196MO (Figure 18CC). Injection of the 
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same dose of XAR1DN mRNA alone resulted in death for majority of the embryos by st30 (data 
not shown). 
 
SGK196 overexpression stimulates neural differentiation in Xenopus animal cap 
The animal cap assays described in this section were performed by Kim Perry and Dr. Jonathan 
Henry.  The Xenopus animal cap assay has been used as a standard to examine the role of various 
inductive signaling pathways. During normal Xenopus early development (at blastula stages) the 
animal-most cap of ectoderm that lies above the hollow blastocoel represents a pluripotent tissue 
capable of generating a variety of cell fates that ultimately contributes to the formation of the 
epidermis as well as neural tissues (Okabayashi and Asashima, 2003, Ariizumi et al., 2009). 
When isolated alone, animal cap tissue obtained from st8-9 embryos forms “atypical” epidermis. 
This is due to the fact that the animal cap, specifically those cells of the ventral region, expresses 
BMP4, which antagonizes the development of neuronal cell fates. Treatment or injecting animal 
caps with agents that antagonize the activity of BMP4, such as noggin, leads to the formation of 
neural fates (Lamb et al., 1993).  
 
The potential activity of Sgk196 to antagonize BMP4 signaling and to stimulate neuronal 
development of the animal cap was tested.  Since sgk196 mRNA is present in animal cap 
ectoderm at st8 of development (Figure 17M), st8 animal caps were isolated from untreated 
control embryos or embryos that had either been injected with synthetic sgk196 mRNA or the 
SGK196MO (Figure 18DD).  Overexpression of sgk196 results in the expression of the pan-
neural marker ncam (Figure 18DD).  In contrast, no ncam expression was detected in control 
untreated animal caps or those isolated from the embryos injected with SGK196MO.  As a 
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further control, it was shown that injection of noggin mRNA led to the expression of ncam in 
animal caps as expected (Figure 18DD).  
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CHAPTER 4 
 
DISCUSSION AND CONCLUSION 
 
 
In this work I identified SGK196 as a key regulator of hESC lineage specification and found 
SGK196 to be a negative regulator of BMP and Activin/TGFβ/Nodal signaling. SGK196 
functions by promoting the degradation of TGFβ family receptors, which is contingent upon 
SGK196-receptor interactions occurring at the SGK196 TM domain.  
 
Despite the lack of conserved catalytic residues within the kinase domain (Figure 1B), SGK196 
has been reported to exhibit in vitro kinase activity on O-mannose, as part of a series of post-
translational modifications leading to the proper post-translational modification of dystroglycan 
(DG) (Jae et al., 2013, Yoshida-Moriguchi et al., 2013). The molecular basis that gives rise to the 
kinase activity was not defined.  Defects in the genes responsible for the DG glycosylation are 
associated with congenital muscular dystrophy (CMD), of which mutations to SGK196 have 
been identified in CMD patients (von Renesse et al., 2014, Yoshida-Moriguchi et al., 2013). In a 
separate study, SGK196 knockout mice were found to develop congenital hydrocephalus and 
exhibited improper neuronal migration in the cerebellum, hippocampus, and cerebral cortex 
tissues (Vogel et al., 2012). The expression of endogenous SGK196 transcript and protein was 
not examined in the mutant mice, and the pathogenic mechanism for the observed defects was 
unclear. Overall, these reports indicate the significance of SGK196 and the diverse roles that this 
molecule may play in other biological functions.  
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In this study I show that SGK196 negatively regulates TGFβ family signaling and accordingly 
influences hESC fate determination. SGK196 depletion results in elevated R-Smad 
phosphorylation in response to BMP4 and Activin A ligand treatment (Figure 2C and 2D).  
Under SGK196 depletion, mesoderm induction is augmented, and endoderm induction appears 
unaffected (Figure 4A and 4C).  In the case of SGK196 overexpression, R-Smad ligand-induced 
phosphorylation is repressed (Figure 2E and 2F), accompanied by inhibition of both mesoderm 
and endoderm specification (Figure 4B and 4D).  These findings are in agreement with 
established reports showing Activin and BMP signaling play an active role in the induction of 
definitive endoderm (D'Amour et al., 2005) and mesoderm (Zhang et al., 2008) differentiation, 
respectively, in hESCs. Inhibition of BMP and Activin/TGFβ signaling, alone or in combination, 
results in neural induction (Chambers et al., 2009, Zhou et al., 2010, Kim et al., 2010, Smith et 
al., 2008).  In line with these studies, upon SGK196 depletion, RA and compound C mediated 
neural induction is repressed (Figure 3A and 3C).  Inhibition of TGFβ family signaling upon 
SGK196 overexpression is also observed in HEK293T cells (Figure 6A and 6B).   
 
Intriguingly, RA-mediated neural induction is not affected by elevated SGK196 levels (Figure 
3D); while Compound C-mediated neural induction appears to be repressed (Figure 3B).  It is 
known that RA and Compound C act through distinct signaling mechanisms to elicit neural 
induction.  In vitro, RA signaling instructively promotes neural differentiation of pluripotent 
cells (Bain et al., 1995, Bibel et al., 2004, Fraichard et al., 1995).  Compound C causes neural 
induction by blocking BMP signaling through the inhibition of type I BMP receptors, ALK2, 
ALK3 and ALK6 (Zhou et al., 2010, Yu et al., 2008, Kim et al., 2010). Emerging evidence 
suggests neural induction is not a simplistic ‘default’ phenomenon occurring in the absence of 
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repressive BMP signaling (Stern, 2006, Stern, 2005), but instead a complex process involving 
instructive signals from FGF, IGF, RA, Wnt pathways and their cross talk with the BMP 
pathway (Sheng et al., 2010, Pera et al., 2003, Pera et al., 2001, Baker et al., 1999, Delaune et al., 
2005, Sasai et al., 1996, Launay et al., 1996, Stern, 2005). It has been also been found that the 
TGFβ family pathway can transduce signals via non-canonical Smad independent pathways, 
including the mitogen-activated protein kinase and RhoA cascades (Zhang, 2009, Derynck and 
Zhang, 2003). Smad independent TGFβ signaling has been shown to be highly relevant in 
pathological states (Iwata et al., 2013, Holm et al., 2011).  The effects from the steady state 
levels of TGFβ family receptors influenced by SGK196 is not necessarily analogous to the 
effects of signaling inhibition by BMP ligand antagonists.  Degradation of TGFβ family receptor 
proteins would result in the overall reduction of any associated receptor-dependent signaling.  
Thereby, I speculate the attenuated neural induction in the presence of SGK196 overexpression 
with repressed BMP signaling, may be due to impacted Smad-independent pathways 
downstream of TGFβ family signaling.  Another speculation is SGK196 could interact with other 
effectors which may consequently affect other pathways.  In both cases the instructive cues 
required for neural induction could be altered.  Further work is needed to address these 
remaining questions. 
 
The TGFβ family pathway controls an extensive array of homeostatic and developmental 
processes. Diverse spatial and temporal regulation is achieved through functional interactions 
with outside effectors, including proteins that modulate the stability and availability of TGFβ 
family receptors (Satow et al., 2006, Aramaki et al., 2010, Onichtchouk et al., 1999, Zhao et al., 
2012, Zhang et al., 2012, Chen, 2009, Zhang and Laiho, 2003, Eichhorn et al., 2012).  I have 
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expanded the mechanistic understanding of the TGFβ family pathway regulation by finding that 
SGK196 can promote the degradation of TGFβ family receptors (Figure 7).  In my studies I 
show that degradation of TGFβ family receptors is likely mediated through specific receptor-
SGK196 interactions occurring at the SGK196 TM domain (Figures 9, 12, and 14).  The 
SGK196 deletion mutant studies demonstrate that the ECD is dispensable for SGK196 activity 
and for BMPR1B interaction, suggesting that SGK196’s ability to promote receptor degradation 
may be kinase independent (Figure 12B, 12E-F).  Mutation of all three Asn31, Asp39, and His40 
polar amino acids residues in the SGK196 TM domain resulted in the decreased interaction with 
BMPR1B, concomitant with the loss of the ability to degrade BMPR1B (Figure 14).  Polar 
residues in the TM domain have been shown to influence receptor trafficking and TM domain 
interactions (Zhou et al., 2001, Nordholm et al., 2013, Cosson et al., 2013, Reggiori et al., 2000, 
Zaliauskiene et al., 2000). Altogether these findings accentuate the link between the SGK196-
receptor interaction and the ability for SGK196 to promote receptor degradation. Further studies 
are needed to understand the nature by which these polar amino acids mediate the SGK196 TM 
domain interactions and the means by which SGK196 promotes the degradation of the TGFβ 
family receptors. Given the differences in the structure and oligomerization between and 
amongst TGFβ family receptor subtypes, the exact nature of the interaction with SGK196 may 
vary among individual receptors (Hinck, 2012, Rechtman et al., 2009, Groppe et al., 2008).  
 
One speculation is SGK196 could function as an adapter, recruiting components linked to these 
degradatory pathways in proximity to SGK196-bound receptors to promote receptor degradation. 
A number of adapters, including I-Smads, Axin and TGIF have been reported to promote the 
degradation of TGFβ family signaling members (Murakami et al., 2003, Liu et al., 2006, Kavsak 
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et al., 2000, Seo et al., 2004). Another speculation is the polar amino acids in the SGK196 TM 
domain may play a role in affecting the trafficking and subsequent degradation of the SGK196-
bound TGFβ family receptors.  
 
To place SGK196 in a developmental context, the expression and function in the model 
vertebrate Xenopus was examined.  sgk196 is expressed broadly during early development, 
including in the animal cap ectoderm (Figure 17A-M). At later stages sgk196 is more highly 
expressed in the CNS and the eye (Figure 17I-L). Consistent with an increased level of BMP and 
Activin/TGFβ signaling, MO-mediated Sgk196 knockdown results in a reduction in the 
development of brain tissues and expanded development of axial mesodermal tissues (e.g., the 
notochord, see Figure 18C-D). These defects could be rescued by co-expression of sgk196 
mRNA (Figure 19Q-T), confirming the specificity of the knockdown. Isolated animal cap 
ectoderm, which normally does not exhibit signs of neural differentiation in culture, expressed 
the pan-neural marker ncam when caps were obtained from embryos injected with sgk196 
mRNA, but not those injected with either SGK196MO or CONMO (Figure 6DD). Interestingly, 
no apparent developmental defects resulted from the expression of sgk196 mRNA alone. 
Correspondingly, it was also observed SGK196 overexpression had little effect on pluripotency 
in hESCs (Figure 1C and Figure 1 - figure supplement 1C). Expression of a dominant negative 
type II activin receptor, ΔXAR1, (called XAR1DN; Figure 18Y-6CC), which blocks many forms 
of TGFβ family signaling (Hemmati-Brivanlou and Melton, 1992; Schulte-Merker et al., 1994) 
leads to severe axial defects in Xenopus embryos. Co-injection of SGK196MO along with 
XAR1DN mRNA resulted in partial rescue of those phenotypes, indicating that the loss of 
Sgk196 activity counteracted some of the repressed TGFβ signaling resulting from expression of 
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the XAR1DN (Figure 18CC). Together, these findings suggest that Sgk196 plays a key role in 
negatively modulating the levels of TGFβ family signaling during Xenopus embryonic 
development. 
 
In this first mechanistic and functional characterization of SGK196, I present novel insight into 
SGK196’s role as an essential regulator for stem cell fate and embryonic development, and as a 
negative regulator of the TGFβ family pathway. I provide evidence suggesting that SGK196 acts 
by promoting the degradation of BMP and TGFβ/Activin receptors to attenuate signaling.  The 
indispensable role of SGK196 in hESCs and Xenopus embryos suggests a conserved function for 
this protein, thereby underscoring the significance of SGK196 activity.  As a regulator of TGFβ 
family signaling, SGK196 may play important roles in other biological processes, which requires 
further investigation.   
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CHAPTER 5 
TABLES AND FIGURES 
 
Table 1.  QPCR primers 
GAPDH 5' CTGGTAAAGTGGATATTGTTGCCAT 3’ 
5' TGGAATCATATTGGAACATGTAAACC 3’ 
SGK196 5' CCACTTCTTCATCGCTCCTC 3’ 
5' ACAGCCAAGGTGAGCAGTTT 3’ 
SOX17 5' GCATGACTCCGGTGTGAATCT 3' 
5' TCACACGTCAGGATAGTTGCAGT 3' 
FOXA2 5' CTGAAGCCGGAACACCACTAC 3' 
5' CGAGGACATGAGGTTGTTGATG 3' 
GSC 5' ACCTCCGCGAGGAGAAAGTG 3' 
5' CTTCTCCGCGTTCTCCGACT 3' 
PAX6 5' GCTTCACCATGGCAAATAACC 3' 
5' GGCAGCATGCAGGAGTATGA 3' 
SOX1 5' AAATGTAGTAAGGCAGGTCCA 3' 
5' ACCCAGAATATAACTCCGCC 3' 
OTX2 5' CAACAGCAGAATGGAGGTCA 3' 
5' ATTGGCCACTTGTTCCACTC 3' 
T 5' CAGCAAAGTCAAGCTCACCA 3' 
5' CCCCAACTCTCACTATGTGGATT 3' 
OCT4 5' GGAGGAAGCTGACAACAATGAAA 3' 
5' GGCCTGCACGAGGGTTT 3' 
SOX2 5' TGCGAGCGCTGCACAT 3' 
5' TCATGAGCGTCTTGGTTTTCC 3' 
NANOG 5' CCAACATCCTGAACCTCAGCTAC 3' 
5' GCCTTCTGCGTCACACCATT 3' 
MIXL1 5' GGCGTCAGAGTGGGAAATCC 3' 
5' GCAGTTCACATCTACCTCAAGAG 3' 
BMPR1B 5' CCCCTCATTCCCAAACCG 3’ 
5' TTAACCCGCAGGGCTGTC 3’ 
BMPR2 5' CTTTACTGAGAATTTTCCACCTCCTG 3’    
5' GCCAAAGCAATGATTATTGTCTCATC 3’   
TGFBR1 5' AAGTCATCACCTGGCCTTGG 3’ 
5' TCGATGGTGAATGACAGTGC 3’ 
TGFBR2 5' GTGTGCCAACAACATCAACC 3’  
5' AGTGTTCTGCTTCAGCTTGG 3’   
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Table 2.  Xenopus primers used in RT-PCR 
ef1a1 5’ CAGATTGGTGCTGGATATGC 3’ 
5’ ACTGCCTTGATGACTCCTAG 3’ 
sxk81a1 5’ CACCAGAACACAGAGTAC 3’ 
5’ CAACCTTCCCATCAACCA 3’ 
ncam1 5’ CACAGTTCCACCAAATGC 3’ 
5’ GGAATCAAGCGGTACAGA 3’ 
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